Key result
Apixaban fails early in a patient with severe morbid obesity and acute pulmonary embolism.
Why the study?
Overall data supporting the efficacy of DOACs for the treatment of VTE in morbidly obese patients or those weighing more than 120 kg are limited, and guidance suggests DOACs should not be used in these populations due to pharmacokinetic concerns.
Case Report (n=1)
No
Highlights a potential risk of apixaban treatment failure for pulmonary embolism in morbidly obese patients.
Answers are grounded in this paper and cite their sources.
Supports avoiding standard-dose apixaban in morbid obesity for PE; reinforces ISTH guidance and leaves open need for weight-specific trials.
To the Editor: As direct oral anticoagulants (DOACs) become the standard-of-care therapy, their use for non-FDAapproved patient populations is under investigation.1,2 Morbidly obese [body mass index (BMI) $40 kg/m2] patients and those with a total body weight .120 kg are 2 populations in which DOACs were not initially approved, yet case reports demonstrate use in clinical practice.3 The International Society on Thrombosis and Haemostasis published guidance in 2016 suggesting DOACs should not be used in the morbidly obese or in patients weighing more than 120 kg.4 Their position was supported by pharmacokinetic data evaluating dabigatran, apixaban, and rivaroxaban that suggested lower peak concentrations and decreased drug exposure with increasing body weight.4 Apixaban use in this population was evaluated in 2 post-hoc analyses of the phase 3 trials that led to FDA approval of apixaban for nonvalvular atrial fibrillation.5,6 Neither analysis found a difference in the incidence of stroke or systemic embolism between warfarin and apixaban.5,6 However, there is concern applying these data to clinical practice given the nature of post-hoc analyses. Retrospective analyses compared the safety and efficacy of DOACs to warfarin in morbidly obese patients.5–9 None of the retrospective analyses reported a statistically significant difference in the incidence of thromboembolic events or in the incidence of bleeding with DOAC therapy compared with warfarin.5–9 Of note, most of these retrospective analyses included only patients with nonvalvular atrial fibrillation and have much larger populations compared with venous thromboembolism (VTE) treatment studies.5,6,8 The retrospective study by Kushnir et al. reviewed patients with a BMI $40 kg/m2 anticoagulated with apixaban, rivaroxaban, or warfarin for the treatment of VTE (n 5 366). They compared the incidence of recurrent thrombotic events in those anticoagulated with apixaban or rivaroxaban (n 5 199) to warfarin (n 5 167). No difference in the incidence of recurrent thrombotic events was reported between the 2 groups, although the incidence of recurrent VTE was low (1.5% and 1.2%, respectively).7 Similar to Kushnir et al.’s study, Perales et al.9 retrospectively compared rivaroxaban (n 5 84) to warfarin (n 5 92) for VTE treatment in morbidly obese patients.9 Of those treated with rivaroxaban, the median weight and BMI were 133 kg and 45 kg/m2, respectively, and 31% were treated for a pulmonary embolism (PE). The overall incidence of recurrent thrombosis was low in both the rivaroxaban and warfarin groups (4% and 6%, respectively), and no significant difference was reported (P 5 0.61). Overall, there is limited data supporting the efficacy of DOACs for the treatment of VTE in morbidly obese patients. This report details a case of apixaban treatment failure in a morbidly obese patient who presented with acute bilateral PEs. A 48-year-old woman presented to the emergency department with a past medical history significant for knee trauma 1 month before admission. Her chief complaint was increasing shortness of breath that developed over 3 to 4 weeks. She was diagnosed with bilateral PEs and a deep vein thrombosis in the right popliteal vein. The patient was morbidly obese with a BMI of 47 kg/m2 (weight 140.6 kg) and an estimated creatinine clearance greater than 100 mL/min (serum creatinine 0.88 mg/dL). Within 5 hours of presentation to the emergency department, The patient was started on IV unfractionated heparin (UFH) titrated to an antiXa level of 0.3–0.7 units/mL. After 24 hours of therapeutic UFH, the patient was transitioned to apixaban 10 mg by mouth every 12 hours. On day 3 of apixaban therapy (after 5 doses), she decompensated with severe, substernal pain, and worsening shortness of breath. Upon review of the electronic medical record, all doses of apixaban were appropriately timed and the patient did not receive any drugs that would decrease apixaban efficacy (e.g., cytochrome P450 American Journal of Therapeutics 0, 1–2 (2020)
No takes yet. Share an insight, caveat, or question.
Scheibner et al. (2020) conducted a case report in Acute bilateral pulmonary embolism and right popliteal deep vein thrombosis in morbid obesity (n=1). Apixaban was evaluated on Clinical treatment failure / decompensation with severe substernal pain and worsening shortness of breath. Apixaban twice daily resulted in clinical treatment failure on day 3 (after 5 doses) in a 48-year-old morbidly obese woman with acute bilateral pulmonary embolisms.
Synapse has enriched 10 related papers. Consider them for comparative context: